MedTrace Logo

Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHN

NCT02426411 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-08-26

No results posted yet for this study

Summary

The study is a randomized, double blind, placebo-controlled, parallel-group comparison (two dose levels of EMA401 versus a placebo group), of safety and efficacy in patients with postherpetic neuralgia.

Conditions

  • Neuralgia, Postherpetic

Interventions

DRUG

EMA401 200 mg

DRUG

EMA401 600 mg

DRUG

Placebo

Sponsors & Collaborators

  • Syneos Health

    collaborator OTHER

  • Spinifex Pharmaceuticals Pty Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-10-31
Completion
2016-12-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02426411 on ClinicalTrials.gov